Allergen Immunotherapy for the Treatment of Eosinophilic Esophagitis. An EAACI Task Force Systematic Review
Clinical and Translational Allergy · 2026-06 · 16 (6)
DOI: 10.1002/clt2.70176 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Clinical and Translational Allergy, online erschienen am 18.06.2026. Verfasst von Martina Votto und 17 weiteren Autor:innen. Beteiligte Einrichtung: Maternity and Pediatric Department, Azienda Sanitaria Locale, Benevento, Italy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The European Academy of Allergy and Clinical Immunology.
Abstract (Originalsprache)
Background
Multiple routes of allergen immunotherapy (AIT) are approved for several IgE‐mediated allergic diseases; however, the use of AIT in eosinophilic esophagitis (EoE) remains controversial and is supported by limited evidence. This review, conducted within the frame of an EAACI Task Force, aims to systematically evaluate the use of AIT as a potential treatment for EoE.
Methods
The protocol was registered and prepared in accordance with PRISMA guidelines. The literature search was conducted across three online databases (PubMed, Embase, and Scopus) and included studies published through January 31 st , 2025. Risk of Bias was assessed for each eligible study.
Results
Four articles met the inclusion criteria. Three articles evaluated EPIT for milk‐induced EoE in pediatric patients, all from the SMILEE (Study of Efficacy and Safety of Viaskin Milk for milk‐induced EoE) trial and its extensions. These included a randomized, placebo‐controlled trial, its open‐label extension, and a pilot immunological study. The SMILEE trial found no statistically significant difference in tissue eosinophilia between the active (EPIT) and control (placebo) arms in the intention‐to‐treat population, while 47% of treated EoE patients tolerated milk without recurrence of esophageal eosinophilia. This finding was further supported by a subsequent open‐label study with a 2‐year follow‐up. In the third publication, the researchers found that EPIT was associated with decreased Th2‐related transcripts and increased regulatory T‐cell‐associated transcripts. Only one eligible study evaluated the use of SCIT for treating EoE. It was a retrospective case‐control study reporting that SCIT had a neutral effect and yielded inconclusive findings regarding the course of EoE.
Conclusion
There is insufficient high‐quality evidence to support the effectiveness of alternative routes of AIT for the treatment of EoE, either as an add‐on or a standalone treatment.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Maternity and Pediatric Department, Azienda Sanitaria Locale, Benevento, Italy.
- Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
- Section of Allergology, Department of Respiratory Medicine and Allergology, Sahlgrenska University Hospital, Gothenburg, Sweden.
- Allergy Department, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Universidad de Alcalá, Madrid, Spain.
- Department of Internal Diseases, Allergology and Clinical Immunology, Medical University of Silesia, Katowice, Poland.
- Department of Allergy and Clinical Immunology, 424 General Military Training Hospital, Thessaloniki, Greece.
ORCID-Profile: Martina Votto, Georgios Rentzos, Darío Antolin-Amerigo, Barbara Rymarczyk, George N Konstantinou, Adam T Fox, Antonella Cianferoni, Arzu Bakirtas, Carlo Maria Rossi, Marina Tsoumani, Enrico Heffler, Ingrid Terreehorst, Evangelia C Apostolidou, Maria Beatrice Biló, Oliver Pfaar, Alfredo J Lucendo, Georgios K Nikolopoulos, Constantinos Pitsios
Förderung
- The European Academy of Allergy and Clinical Immunology
Zitieren
APA
Votto, M., Rentzos, G., Antolin-Amerigo, D., Rymarczyk, B., Konstantinou, G. N., Fox, A. T., Cianferoni, A., Bakirtas, A., Rossi, C. M., Tsoumani, M., Heffler, E., Terreehorst, I., Apostolidou, E. C., Biló, M. B., Pfaar, O., Lucendo, A. J., Nikolopoulos, G. K., & Pitsios, C. (2026). Allergen Immunotherapy for the Treatment of Eosinophilic Esophagitis. An EAACI Task Force Systematic Review. Clinical and Translational Allergy, 16(6). https://doi.org/10.1002/clt2.70176
Vancouver
Votto M, Rentzos G, Antolin-Amerigo D, Rymarczyk B, Konstantinou GN, Fox AT, et al. Allergen Immunotherapy for the Treatment of Eosinophilic Esophagitis. An EAACI Task Force Systematic Review. Clinical and Translational Allergy. 2026;16(6). doi:10.1002/clt2.70176
BibTeX
@article{Votto2026,
author = {Votto, Martina and Rentzos, Georgios and Antolin-Amerigo, Darío and Rymarczyk, Barbara and Konstantinou, George N and Fox, Adam T and Cianferoni, Antonella and Bakirtas, Arzu and Rossi, Carlo Maria and Tsoumani, Marina and Heffler, Enrico and Terreehorst, Ingrid and Apostolidou, Evangelia C and Biló, Maria Beatrice and Pfaar, Oliver and Lucendo, Alfredo J and Nikolopoulos, Georgios K and Pitsios, Constantinos},
title = {Allergen Immunotherapy for the Treatment of Eosinophilic Esophagitis. An EAACI Task Force Systematic Review},
journal = {Clinical and Translational Allergy},
year = {2026},
volume = {16},
number = {6},
doi = {10.1002/clt2.70176}
}
EUVIMED